Skip to content
IVOIVOIVO250250250

Drawing based on the description in the official product monograph. No photo yet.

“6 . DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING. . Table 2 -. Dosage Forms, Strengths,. Composition and Packaging Route of Administration oral Dosage Form / Strength/Composition Tablet 250 mg Non-medicinal Ingredients Colloidal silica (anhydrous), Croscarmellose sodium, Hypromellose, Hypromellose acetate succinate, Indigo carmine aluminum lake, Lactose monohydrate, Magnesium stearate, Micro”

IVO 250 pill

Pill with imprint IVO 250 is blue, oval, 18 mm and has been identified as Ivosidenib 250 mg. It is used for acute myeloid leukemia. It is supplied by Servier Canada Inc.

Sold in Canada

Ivosidenib 250 mg

Brand
Tibsovo
Imprint
IVO 250
Strength
250 mg
Used for
Acute myeloid leukemia
Color
Blue
Shape
Oval
Size
18 mm
Form
Tablet (immediate-release)
Manufacturer
Servier Canada Inc
Drug class
Isocitrate dehydrogenase 1 inhibitor
Sold in
Canada
DIN
02549980

Source: Health Canada's Drug Product Database and the official product monograph. Last checked .

Report a mistake

Please do not include personal health information. For questions about your medicine, ask a pharmacist.

All Ivosidenib pills and guides

What is Ivosidenib used for?

Ivosidenib is used for acute myeloid leukemia.

Medicine type
Isocitrate dehydrogenase 1 inhibitor
Official uses from the US prescribing label

Newly Diagnosed Acute Myeloid Leukemia

TIBSOVO is indicated in combination with azacitidine or as monotherapy for the treatment of newly diagnosed acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.

Relapsed or Refractory Acute Myeloid Leukemia

TIBSOVO is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.

Relapsed or Refractory Myelodysplastic Syndromes

TIBSOVO is indicated for the treatment of adult patients with relapsed or refractory myelodysplastic syndromes (MDS) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.

Locally Advanced or Metastatic Cholangiocarcinoma

TIBSOVO is indicated for the treatment of adult patients with previously treated, locally advanced or metastatic cholangiocarcinoma with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.

From the FDA-approved label on DailyMed (published Dec 22, 2025).

Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.

Is this your pill? Check every detail

  • Your pill shows IVO 250. The parts can be split between the two sides, so turn the pill over and check both.
  • It is blue, oval, 18 mm.
  • Its score line and coating match the details on this page.
  • It came from a pharmacy package that names the same drug.

Sold in Canada as Tibsovo by Servier Canada Inc.

In Canada: prescription only.

Ingredients

Active: Ivosidenib

Other pills with imprint IVO 250

Same imprint, different listing. Check the color, size and maker against your pill.

Pills that look similar but are different drugs

Same color and shape, different medicine. This is why the imprint matters.